Laakmann Elena, Riecke Kerstin, Goy Yvonne, Kersten Jan F, Krüll Andreas, Müller Volkmar, Petersen Cordula, Witzel Isabell
Department of Gynecology, University Medical Center, Martinistrasse 52, 20246, Hamburg, Germany.
Department of Radiotherapy, University Medical Center, Martinistrasse 52, 20246, Hamburg, Germany.
J Cancer Res Clin Oncol. 2016 Jan;142(1):325-32. doi: 10.1007/s00432-015-2049-4. Epub 2015 Sep 30.
Several prognostic indices (PI) have been developed to stratify patients with brain metastases in groups with good or bad prognosis. The aim of our study was to compare nine prognostic scores for patients with brain metastases (BM) of breast cancer receiving radiotherapy.
The clinical data of 139 breast cancer patients with BM were collected retrospectively. All patients were treated with cerebral radiotherapy or surgery followed by radiotherapy between January 2007 and December 2012. The prognostic value and accuracy of recursive partitioning analysis (RPA), RPA II, graded prognostic assessment (GPA), basic score for BM, Breast-RPA, Breast-GPA, Rades Score 2011, Germany Score and Breast Rades Score were assessed.
The median survival after BM diagnosis in our cohort was 14 months. The overall 6-month, 1-, 2- and 3-year survival rates were 49.6, 37.4, 20.9 and 13.7 %, respectively. Most of the PI were associated with OS, but univariate analysis favored GPA regarding OS. GPA was the most accurate score to identify patients with long (longer than 12 months) and Breast-GPA patients with short (<3 months) life expectancy.
GPA and Breast-GPA seem to be the most useful scores and perform better than other PI for breast cancer patients with BM receiving radiotherapy.
已开发出多种预后指数(PI),用于将脑转移患者分层为预后良好或不良的组。我们研究的目的是比较接受放疗的乳腺癌脑转移(BM)患者的九种预后评分。
回顾性收集139例乳腺癌BM患者的临床资料。所有患者在2007年1月至2012年12月期间接受了脑部放疗或手术,随后进行放疗。评估递归划分分析(RPA)、RPA II、分级预后评估(GPA)、BM基本评分、乳腺癌-RPA、乳腺癌-GPA、2011年拉德斯评分、德国评分和乳腺癌拉德斯评分的预后价值和准确性。
我们队列中BM诊断后的中位生存期为14个月。总体6个月、1年、2年和3年生存率分别为49.6%、37.4%、20.9%和13.7%。大多数PI与总生存期(OS)相关,但单因素分析在OS方面更支持GPA。GPA是识别预期寿命长(超过12个月)的患者和乳腺癌-GPA识别预期寿命短(<3个月)的患者最准确的评分。
对于接受放疗的乳腺癌BM患者,GPA和乳腺癌-GPA似乎是最有用的评分,并且比其他PI表现更好。